,,, A ECs,, A ECs,,, A ECs,,,, ( 8) 213 3,,,,,, A ECs,, ( 9) 7,,,,,, ( 10),,, 28,,A ECs,,A ECs, A ECs 7 ;, ( ) ( 11) 3 BL M IPF, IPF [2

Size: px

Start display at page:

Download ",,, A ECs,, A ECs,,, A ECs,,,, ( 8) 213 3,,,,,, A ECs,, ( 9) 7,,,,,, ( 10),,, 28,,A ECs,,A ECs, A ECs 7 ;, ( ) ( 11) 3 BL M IPF, IPF [2"

碗丸崔
9 years ago
Views:

1 512 Chinese Medical Journal of Metallurgical Industry,October 2005,Vol122 No ( ) 2 : : (5 mg/ kg), : 3, ; 7 :,, ; 28 :,,, :, R 563 A (2005) Ultrastructural feature of experimental lung injury and pulmonary f ibrosis of rat induced by bleomycin1 RU Yong2x in 1, Z HA N G H ua2mei 1, L IU J in2 hua 1, et al1 I nstitute of Hematology & B lood Diseases Hos pital, Peking Union College 1, Tianj in, Abstract Objective :To observe and analyze ultrastructural pat hological processes of pulmonary fibrosis of rat2induced by bleomycin1 Methods : The injured lungs were investigated by electron microscopy ( TEM) on 3 7 and 28 day after intratracheal administration of bleomycin ( 5 mg/ kg) respectively1 Results :On 3 day,the ultrastructural characteristics of lung injure included alveolar epithelial cells ( A EC) damage and breakdown, alveolitis infiltrated by neutrophi, expended capillary1 The pathological features on 7 day comprehended alveolitis and interstitial inflammation conducted mainly by macrophages,coexistent of alveolar collapse and expending,increasing of interstitial component s1 The performance of lungs on 28 days induced by BL M included large alveoli,concomitance of damage and proliferation of A EC -,granulomatosis of lung1 Conclusions : The pathological distinctions of A EC,capillary,inflammatory cell,and the nature of consolidation of tissue can be illustrated dynamically by TEM1 Key Words Lung injury Fibrosis Ultrastructural characteristics (p ulmonary fibro sis, PF) (extracellular matrix deposition,ecm), [ 1 ] PF, (BL M) PF, ( alveolar epit helial cell,a EC), 1 SD ( ) 48, g,4, (BL M), ml/ 100 g ;BL M BL M 5 mg/ kg, , 6 %, ; H ,,,, ;, ( 1,2) 7,,, 12 m,, ;,, ( 3,4) 28,,,, A ECs,, ( 5) A ECs,,,,,,, A ECs, ; A ECs,,, ( 6) 7 A ECs,,,,, ( 7) 28 A ECs 3 : : 13

2 ,,, A ECs,, A ECs,,, A ECs,,,, ( 8) 213 3,,,,,, A ECs,, ( 9) 7,,,,,, ( 10),,, 28,,A ECs,,A ECs, A ECs 7 ;, ( ) ( 11) 3 BL M IPF, IPF [2 ] BL M PF, ACE BL M 7 A ECs,, ;,,, ;, ; ( ), PF, BL M 28,A ECs,,,, A ECs PF, PF A ECs,,,, ; A ECs PF,, PF,,, PF,,, PF [6,7 ] 10,, PF [8 ],,,, PF,, ;, ;, [3 5 ] 3,,,, PF,, PF,,A ECs ;,,, A ECs, PF,, ( , 3) BL M A ECs,, PF 1 Fang X, Zhu Y, Hu X, Liu Y 1 Losartan in t he rat model of bleomycin - induced pulmonary fibrosis and its impact on the expression of monocyte chemoattractant protein - 1 and basic fibroblast growt h factor1 Zhonghua Jie He He Hu Xi Za Zhi,2002 ; 25 (5) :268

3 514 Chinese Medical Journal of Metallurgical Industry,October 2005,Vol122 No1 5 2, 1 1,1998 ; 15 (4) : Rilke F, Pilotti S1 Pulmonary histopat hological changes in subject s with malignant tumors treated with bleomycin1 Tutorial : Tumori, 1971 ;57 (4) :287 4 Jones AW1Bleomycin lung damage :the pat hology and nature of the lesion1br J Dis Chest,1978 ;72 (4) :321 5 Ross, T1 J1 & Hunninghake, G1 W1 Idiopat hicpulmonaryfibrosis1 N1 Engl1J1 Med,2001 ;345 :517 6 Vaillant P1Biopat hology of fibrosing alveolitis1 Rev Prat,1991 ; 41 (14) : Kasper M 1 Distribution of von Willebrand factor in capillary endothelial cells of rat lungs wit h pulmonary fibrosis1 Exp Toxicol Pathol,1996 ;48 (4) :283 8,,, 1 1,2003 ;11 (2) :78 ( ) ( ) 2 1,,66 5 : T 3615, P 84 /, R 21 /,Bp 160/ 75 mm Hg,, 84 /,,,, : / L, / L, 56 g/ L, / L + +, g/ L, 3217 g/ L, 8719 g/ L, 3196 mmol/ L, 7161 mmol/ L, mol/ L, mmol/ L, 650 mmol/ L A %, %, %, 61 6 %, %, M : 40 % 3, mmol/ L, 1050 mol/ L, 1712 mmol/ L ; 6112 mmol/ L : A K - 90, N IPRO FB A GA P2S, 2, ml/ min, 2000 ml, 2000 ml ( 1000 ml,5 % 500 ml, 500 ml) 2, 200 ml/ min, 500 ml/ min, 015 kg, 2 : (10 9 / L) (g/ L) (10 9 / L) (g/ L) (g/ L) (mmol/ L) ( mol/ L) (mmol/ L) (mmol/ L) (mmol/ L) : ,72, ml, 2,,,, -,,,, ( )

21 13 D / 2 10 ig ig 10 d 1. 0 g kg /2 2 β- 5 g kg g kg mg kg - 1 ig ig 24 h 5% 1 2% CMC-Na 2. 5 ml 30

21 13 D / 2 10 ig ig 10 d 1. 0 g kg /2 2 β- 5 g kg g kg mg kg - 1 ig ig 24 h 5% 1 2% CMC-Na 2. 5 ml 30 21 13 1 2 1* 2 1. 430065 2. 445000 20 10 5 g kg - 1 5 mg kg - 1 ig 10 d ig HE 1 TFF1 TFF1 P < 0. 01 P < 0. 01 P < 0. 01 P < 0. 05 R285. 5 doi 10. 13422 /j. cnki. syfjx. 2015130100 A 1005-9903 2015 13-0100-05